Actualités et Activités de Serb Pharmaceuticals

Serb Pharmaceuticals a une présence directe dans 2 pays.

Elles sont en:

• Pharmacie50%
• Biotechnologie50%

Acquisition, funding and merger involving Serb Pharmaceuticals.

• Serb Pharmaceuticals a acquis Y-mAbs Therapeutics (publié le 17 septembre 2025).
• Serb Pharmaceuticals has announced the acquisition of Y-mAbs Therapeutics  (publié le 6 août 2025).

Voir l'organigramme avec ses 35 principaux dirigeants

Biographies les plus recherchées chez Serb Pharmaceuticals

• Vanessa Wolfeler, Chief Executive Officer
• Jeremie Urbain, Chairman of the Board
• Arthur Pignot, Chief Strategy Officer

Changements de dirigeants chez Serb Pharmaceuticals

• Cecile Baradez, a rejoint l'entreprise comme Medical Science Liaisons Director  (publié le 11 mai 2026).
• Neha Chawla qui était Senior Director, Commercial Operations, est promu Executive Director, Commercial Operations  (publié le 24 mars 2026).

Créer une alerte
pour suivre les mouvements de dirigeants chez Serb Pharmaceuticals.

Serb Pharmaceuticals a 1 913 concurrents dont Sanofi (France), Eli Lilly (Etats—Unis) et Moderna (Etats—Unis).

Actualités en fusion/acquisition en Pharmacie.

• Contraline vient d'annoncer une levée de fonds de 93 millions de dollars. (publié le 3 juin 2026).
• Hims & Hers a acquis Eucalyptus (publié le 2 juin 2026).
• Apotex a déposé son dossier d'introduction en bourse. Son symbole boursier sera TSX. (publié le 2 juin 2026).

Contacts en Pharmacie

• Joaquin Duato - Chief Executive Officer and Chairman of the Board chez Johnson & Johnson
• Richard Saynor - Chief Executive Officer chez Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board chez Abbott

En savoir plus sur le secteur Pharmacie

Derniers communiqués de presse par Serb Pharmaceuticals

• SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million - SERB Pharmaceuticals
• SERB Pharmaceuticals Announces ThyroSafe 130mg Potassium Iodide Tablets are Now Commercially Available in the US - SERB Pharmaceuticals
• Y-mAbs Announces Publication in Cancers - SERB Pharmaceuticals
• SERB Pharmaceuticals Expands Scientific Leadership with Appointment of Dr. Peter C. Adamson to US Board  - SERB Pharmaceuticals
• Dr. Vignesh Rajah Appointed as SERB Pharmaceuticals’ Chief Medical Officer - SERB Pharmaceuticals
• SERB Pharmaceuticals Completes Acquisition of Y-mAbs Therapeutics - SERB Pharmaceuticals
• SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics - SERB Pharmaceuticals
• SFJ Pharmaceuticals and SERB Pharmaceuticals Present Positive Final Results from Pivotal Phase 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Surgery or Experiencing Major Bleeding  - SERB Ph
• Newly published study shows that Voraxaze® can improve clinical outcomes in patients with high-dose methotrexate induced acute kidney injury - SERB Pharmaceuticals
• First FDA-approved treatment for severe frostbite now commercially available in the US  - SERB Pharmaceuticals
• Voir plus de communiqués de presse Close

Réseaux sociaux à propos de Serb Pharmaceuticals

• Serb Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
• Serb Pharmaceuticals sur LinkedIn, X (Twitter) & YouTube en 1-click